SECONDARY METABOLITE SCREENING SYSTEM
The present invention relates to systems and methods for screening natural products such as secondary metabolites produced by engineered microbial strains.
1 . A method for screening for bioactive agents, comprising:
providing a cell or organism exhibiting a measurable phenotype, wherein the organism is selected from a fungus, protist, hydrozoa, planaria, nematode, insect, plant or plant part, or microbe;
contacting the cell or organism with a microbial library or material derived therefrom, the microbial library producing a library of secondary metabolites through combinatorial expression of synthetic genes, and
identifying secondary metabolites that affect the measurable phenotype.
2 . (canceled)
3 . The method of claim 1 , wherein the microbial strain is engineered to lyse upon a selected stimulus, and the cell or organism is optionally a cell line or non-bacterivorous organism.
4 . The method of claim 1 , wherein the organism is a protozoan, a cnidarian, a flatworm, an arthropod, an amoeba, a paramecium, or a nematode.
5 - 9 . (canceled)
10 . The method of claim 3 , wherein the organism or cell is a plant cell, plant, or plant part; cell of a vertebrate organism; an embryo; or a fungi or yeast.
11 . (canceled)
12 . (canceled)
13 . The method of claim 1 , wherein the organisms or cells are plated in wells of a multiwell plate.
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . The method of claim 13 , wherein the organism is C . elegans , and worms are dispensed into wells at L1 stage, L2 stage, L3 stage, L4 stage, dauer stage, or adult stage.
18 . The method of claim 13 , wherein the organism is C . elegans , and the C . elegans are contacted with the microbial strain or material derived there from at L1 stage, L2 stage, L3 stage, L4 stage, dauer stage, or adult stage.
19 . (canceled)
20 . The method of claim 1 , wherein the effect on said measurable phenotype is quantified by the level of protein expression of a reporter gene and/or cellular location of the reporter gene RNA or protein, or impact on morphology or motility.
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . The method of claim 1 , wherein the microbial strain is a bacterium, archaea, fungus, or yeast.
25 . (canceled)
26 . (canceled)
27 . (canceled)
28 . (canceled)
29 . The method of claim 1 , wherein the measurable phenotype is detected or quantified by: dye staining; immunochemistry, gene expression analysis, which is optionally by qRT-PCR, polynucleotide sequencing, and/or polynucleotide hybridization analysis, such as microarray or FISH.
30 . (canceled)
31 . The method of claim 1 , wherein the measurable phenotype is induction or reduction of gene expression or protein expression, protein modification, metabolism, change in metabolic or physiologic state, subcellular or tissue structure and organization, protein or RNA stability, epigenetic modification, cell or organism death, lifespan extension, autophagy, organellar structure and function, intracellular or intercellular trafficking or signaling, neuronal functioning, cell proliferation, RNA toxicity, a stress response, a pathogen response, calcium influx, fat storage, developmental timing, brood size, or behavior such as social feeding or food avoidance.
32 . The method of claim 1 , wherein the measurable phenotype is determined by assaying pathogen response, stress response, detoxification, hypoxia response, unfolded protein response, mitochondrial marker(s), RNAi function, piRNA function, microRNA function, proteasome function, and/or the measurable phenotype is the activity of a subcellular or intercellular signaling pathway.
33 . An in vitro method for screening for active agents, comprising: providing a microbial strain that has been engineered to lyse upon a selected stimulus and which produces a library of secondary metabolites synthesized by combinatorial expression of one or more heterologous genes, adding the microbial strain or material derived therefrom to an in vitro assay, and identifying whether the secondary metabolite has a measurable activity in the in vitro assay.
34 . The method of claim 33 , wherein the microbial strain or material derived therefrom is plated in wells of a multiwell plate.
35 . (canceled)
36 . The method of claim 33 any, wherein the microbial strain is a bacterium, archaea, fungus, or yeast.
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . The method of claim 33 , wherein the secondary metabolite is a terpene, terpenoid, alkaloid, cannabinoid, steroid, saponin, glycoside, stilbenoid, polyphenol, flavonoid, antibiotic, polyketide, fatty acid, or a non-ribosomal peptide.
41 . The method of claim 40 , wherein the secondary metabolite is a terpene or terpenoid.
42 . (canceled)
43 . The method of claim 41 , wherein the library of microbial strains expresses a library of terpene synthases.
44 . (canceled)
45 . The method of claim 43 , wherein the microbial strain overexpresses one or more of a geranyl diphosphate synthase (GPS), a geranylgeranyl diphosphate synthase (GGPS), a farnesyl diphosphate synthase (FPS), and a farnesyl geranyl diphosphate synthase (FGPPS).
46 . (canceled)
47 . The method of claim 41 , wherein the microbial strains express a library of P450 oxidase enzymes.
48 . The method of claim 41 , wherein the microbial strains express a library of uridine diphosphate dependent glycosyltransferase (UGT) enzymes, methyltransferase enzymes, acetyltransferase enzymes, and/or benzoyl transferase enzymes.
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . The method of claim 33 , wherein bioactive secondary metabolites are produced by fermentation of corresponding microbial strains, optionally optimized for production yield.